Active Pharmaceutical Ingredient API News and Research

RSS

Perrigo net sales increase 18% to $920M in third quarter 2013

Perrigo Company today announced results for its third quarter ended March 30, 2013.Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with our performance, as the team delivered all-time record quarterly revenue and adjusted diluted earnings per share.

7 May 2013

Synthesis & Solid State Pharmaceutical Centre: an interview with Dr Mary Shire, University of Limerick

This is a new research centre led by the University of Limerick that supports the pharmaceutical sector in Ireland. The centre will carry out research on the key aspects of what it takes to synthesise the pharmaceutically active molecule to isolate a pure material and to formulate this into a medicine.

14 Mar 2013

Sanofi, DBV Technologies partner to produce Viaskin's Active Pharmaceutical Ingredients

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergies, announced today that it entered into a strategic manufacturing agreement with Sanofi to produce Viaskin's Active Pharmaceutical Ingredients (API), such as the peanut protein extract.

5 Mar 2013

Microcystins in drinking water

An interview with Rohan Thakur, discussing the prevalence of microcystins in drinking water, and the use of LC-MS to identify cyanotoxins within water samples.

From Bruker Daltonics 5 Mar 2013

USP evaluates Raman device's potential to detect counterfeit and substandard medicines

With substandard and counterfeit medicines a dangerous and growing problem in the developing world and elsewhere, identifying new technologies to detect such drugs is an urgent matter. In a new study published in the Journal of Pharmaceutical and Biomedical Analysis, scientists from the U.S. Pharmacopeial Convention (USP) evaluated a handheld Raman device's potential to detect counterfeit and substandard medicines.

21 Feb 2013

U.S. Marshals seize tainted dietary supplements from Globe All Wellness

U.S. Marshals, acting on behalf of the U.S. Food and Drug Administration, today seized tainted dietary supplements from Globe All Wellness, LLC (Globe All), in Hollywood, Fla. The products may be unsafe because they contain an undisclosed active pharmaceutical ingredient.

15 Feb 2013

Tianyin Pharmaceutical second quarter revenue decreases 3.3% to $17.6 million

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.

14 Feb 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

Glenmark third quarter consolidated revenue increases 33.96% to Rs. 13812.59M

Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its results for the third quarter ended December 31, 2012.

30 Jan 2013

AACN 2013 National Teaching Institute & Critical Care Exposition to be held in Boston

The American Association of Critical-Care Nurses (AACN) invites nurses and other healthcare professionals who care for high acuity and critically ill patients and their families to its 2013 National Teaching Institute & Critical Care Exposition (NTI) in Boston May 20-23, with preconferences May 18-19.

29 Jan 2013

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Asian and Pacific Islander diabetes data need segregating

Surveillance statistics that aggregate Asians and Pacific Islanders are misleading in terms of establishing who would benefit most from increased diabetes prevention interventions, report US researchers.

17 Oct 2012

Catalent licenses NJIT’s taste-making technology to mask unpleasant and bitter medicines

Following a successful research collaboration with NJIT, Catalent Pharma Solutions of Somerset has announced that it has exclusively licensed innovative taste-making technology developed by NJIT Distinguished Professor Rajesh Dav-, who was the principal investigator of a research project funded by Catalent. The technology will mask the most challenging, unpleasant and bitter tasting pharmaceutical active ingredients.

11 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Tianyin Pharmaceutical sales decrease 26.9% to $69.6 million for fiscal year 2012

28 Sep 2012

U.S. Pharmacopeial announces winners of 2012-13 Global Fellowship awards

Since the program's inception more than thirty years ago, USP has invested nearly $4 million in over 200 fellowship awards.

28 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Wockhardt receives FDA marketing approval for Lansoprazole

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, which is used in treatment of peptic ulcers. Lansoprazole is the generic name for the brand Prevacid, marketed in the United States by Takeda. Wockhardt is launching the product immediately.

17 Sep 2012

Zhejiang Hisun Pharmaceuticals, Pfizer launch new joint venture

Pfizer Inc., the world's largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals, a leading Chinese pharmaceutical company, today announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

13 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012